SS18 and synovial sarcoma: Consistently, A-485 blocks tumorigenicity of onco-condensate validated by EdU cell proliferation assay (Fig. 5c, d) and tumor-bearing mouse models constructed by SW982 with overexpression of SS18-SSX (Fig. 5e, Supplementary Fig. 13c, d) and synovial sarcoma cell line HS-SY-II (Supplementary Fig. 13e-g), which suggested that targeting H3K27ac histone modification may be efficacious for treating synovial sarcoma carrying SS18-SSX.